{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T12:10:14Z","timestamp":1789128614453,"version":"build-2803163510"},"reference-count":32,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2021,9]]},"abstract":"<jats:p>Dezocine is an opioid with low efficacy at \u03bc-opioid and \u03ba-opioid receptors. It also inhibits the reuptake of norepinephrine and serotonin. Dezocine is an effective analgesic against various clinical painful conditions and is widely used in many Asian countries. Given the unique pharmacology of dezocine, the drug may also have antidepressant-like properties. However, no published preclinical study has explored this possibility. This study examined the potential antidepressant-like activity of dezocine in mice. Male ICR mice were used in the forced swimming test, the tail suspension test, the warm water tail withdrawal test and locomotor activity test to test the effects of dezocine (0.3\u20133.0 mg\/kg). The 5-HT<jats:sub>1A<\/jats:sub> receptor antagonist WAY-100635 (1 mg\/kg), the \u03bc-opioid receptor antagonist \u03b2-funaltrexamine (2 mg\/kg) and the \u03ba-opioid receptor agonist U50488 (1 mg\/kg) were also studied in combination with dezocine. Dezocine produced a dose-dependent decrease in the immobility time in the forced swimming test and tail suspension test at doses that did not alter the motoric activity as determined in the locomotion test. WAY-100635 and U50488 but not \u03b2-funaltrexamine pretreatment significantly blocked the effects of dezocine. Dezocine dose-dependently increased the latency in the tail withdrawal test which was blocked by WAY-100635 and \u03b2-funaltrexamine. Combined, these results suggest that dezocine may have antidepressant-like effects. Considering the well-documented analgesic property of dezocine, it may be useful to treat pain and depression comorbidity.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000641","type":"journal-article","created":{"date-parts":[[2021,6,8]],"date-time":"2021-06-08T21:05:19Z","timestamp":1623186319000},"page":"472-478","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":10,"title":["Antidepressant-like effects of dezocine in mice: involvement of 5-HT1A and \u03ba opioid receptors"],"prefix":"10.1097","volume":"32","author":[{"given":"Li","family":"Shang","sequence":"first","affiliation":[{"name":"Department of Nursing"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunhao","family":"Duan","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Yantai Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shui","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Affiliated Hospital, Binzhou Medical University, Yantai, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Yantai Affiliated Hospital, Binzhou Medical University, Yantai, Shandong Province, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shushan","family":"Jia","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology, Yantai Affiliated Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2021,6,3]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1001\/archinte.163.20.2433","article-title":"Depression and pain comorbidity: a literature review.","volume":"163","author":"Bair","year":"2003","journal-title":"Arch Intern Med"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1038\/npp.2009.183","article-title":"Antidepressant-like effects of kappa-opioid receptor antagonists in Wistar Kyoto rats.","volume":"35","author":"Carr","year":"2010","journal-title":"Neuropsychopharmacology"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"2731","DOI":"10.1097\/00007632-199512150-00015","article-title":"Psychologic distress and low back pain. Evidence from a prospective study in the general population.","volume":"20","author":"Croft","year":"1995","journal-title":"Spine (Phila Pa 1976)"},{"key":"R4-20250614","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.euroneuro.2004.01.004","article-title":"5-HT1A receptors are differentially involved in the anxiolytic- and antidepressant-like effects of 8-OH-DPAT and fluoxetine in the rat.","volume":"14","author":"De Vry","year":"2004","journal-title":"Eur Neuropsychopharmacol"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1097\/00002508-199106000-00004","article-title":"Clinical aspects of depression in chronic pain patients.","volume":"7","author":"Dworkin","year":"1991","journal-title":"Clin J Pain"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/j.jpain.2018.01.002","article-title":"A kappa opioid receptor agonist blocks bone cancer pain without altering bone loss, tumor size, or cancer cell proliferation in a mouse model of cancer-induced bone pain.","volume":"19","author":"Edwards","year":"2018","journal-title":"J Pain"},{"key":"R7-20250614","first-page":"18","article-title":"Double-blind, placebo-controlled, proof-of-concept trial of a kappa-selective opioid receptor antagonist augmentation in treatment-resistant depression.","volume":"32","author":"Fava","year":"2020","journal-title":"Ann Clin Psychiatry"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.2174\/1570159X17666190811161807","article-title":"Targeting Serotonin1A receptors for treating chronic pain and depression.","volume":"17","author":"Haleem","year":"2019","journal-title":"Curr Neuropharmacol"},{"key":"R9-20250614","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1016\/S0028-3908(02)00330-1","article-title":"Behavioral action of ethanol in Porsolt\u2019s forced swim test: modulation by 3 alpha-hydroxy-5 alpha-pregnan-20-one.","volume":"43","author":"Hirani","year":"2002","journal-title":"Neuropharmacology"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"3715","DOI":"10.1007\/s00213-020-05649-y","article-title":"The kappa opioid receptor antagonist aticaprant reverses behavioral effects from unpredictable chronic mild stress in male mice.","volume":"237","author":"Jacobson","year":"2020","journal-title":"Psychopharmacology (Berl)"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2015.12.039","article-title":"The 5-HT1A receptor in major depressive disorder.","volume":"26","author":"Kaufman","year":"2016","journal-title":"Eur Neuropsychopharmacol"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/7854_2010_108","article-title":"Animal models of depression: molecular perspectives.","volume":"7","author":"Krishnan","year":"2011","journal-title":"Curr Top Behav Neurosci"},{"key":"R13-20250614","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1001\/archfami.3.9.774","article-title":"Physical symptoms in primary care. Predictors of psychiatric disorders and functional impairment.","volume":"3","author":"Kroenke","year":"1994","journal-title":"Arch Fam Med"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.bbr.2014.04.042","article-title":"Pain and depression comorbidity: a preclinical perspective.","volume":"276","author":"Li","year":"2015","journal-title":"Behav Brain Res"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"107494","DOI":"10.1016\/j.pharmthera.2020.107494","article-title":"A hypothesis of monoamine (5-HT) - Glutamate\/GABA long neural circuit: aiming for fast-onset antidepressant discovery.","volume":"208","author":"Li","year":"2020","journal-title":"Pharmacol Ther"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"714","DOI":"10.1097\/ALN.0000000000000076","article-title":"Novel molecular targets of dezocine and their clinical implications.","volume":"120","author":"Liu","year":"2014","journal-title":"Anesthesiology"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/0304-3959(93)90076-2","article-title":"Chronic musculoskeletal pain and depressive symptoms in the National Health and Nutrition Examination. I. Epidemiologic follow-up study.","volume":"53","author":"Magni","year":"1993","journal-title":"Pain"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"173062","DOI":"10.1016\/j.ejphar.2020.173062","article-title":"Dual \u03bc-opioid receptor and norepinephrine reuptake mechanisms contribute to dezocine- and tapentadol-induced mechanical antiallodynia in cancer pain.","volume":"876","author":"Mao","year":"2020","journal-title":"Eur J Pharmacol"},{"key":"R19-20250614","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1192\/bjp.139.4.293","article-title":"Physical symptoms of depression.","volume":"139","author":"Mathew","year":"1981","journal-title":"Br J Psychiatry"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.2174\/156802606778522195","article-title":"The role of 5-HT1A receptors in research strategy for extensive pain treatment.","volume":"6","author":"Mico","year":"2006","journal-title":"Curr Top Med Chem"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/s41380-018-0117-2","article-title":"Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches.","volume":"24","author":"Peci\u00f1a","year":"2019","journal-title":"Mol Psychiatry"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/0014-2999(78)90414-4","article-title":"\u201cBehavioural despair\u201d in rats and mice: strain differences and the effects of imipramine.","volume":"51","author":"Porsolt","year":"1978","journal-title":"Eur J Pharmacol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1001\/archgenpsychiatry.2009.36","article-title":"Cross-national associations between gender and mental disorders in the World Health Organization World Mental Health Surveys.","volume":"66","author":"Seedat","year":"2009","journal-title":"Arch Gen Psychiatry"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/S0009-9236(96)90137-X","article-title":"Opioid antagonist effects of dezocine in opioid-dependent humans.","volume":"60","author":"Strain","year":"1996","journal-title":"Clin Pharmacol Ther"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/BF00428203","article-title":"The tail suspension test: a new method for screening antidepressants in mice.","volume":"85","author":"Steru","year":"1985","journal-title":"Psychopharmacology (Berl)"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1021\/acs.jmedchem.6b01827","article-title":"Triple reuptake inhibitors as potential therapeutics for depression and other disorders: design paradigm and developmental challenges.","volume":"61","author":"Subbaiah","year":"2018","journal-title":"J Med Chem"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"43137","DOI":"10.1038\/srep43137","article-title":"Dezocine exhibits antihypersensitivity activities in neuropathy through spinal \u03bc-opioid receptor activation and norepinephrine reuptake inhibition.","volume":"7","author":"Wang","year":"2017","journal-title":"Sci Rep"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"14087","DOI":"10.1038\/s41598-018-32568-y","article-title":"Pharmacological characterization of dezocine, a potent analgesic acting as a \u03ba partial agonist and \u03bc partial agonist.","volume":"8","author":"Wang","year":"2018","journal-title":"Sci Rep"},{"key":"R29-20250614","first-page":"5","article-title":"The anti-nociception effect of dezocine in a rat neuropathic pain model.","volume":"1","author":"Wu","year":"2014","journal-title":"Transl Perioper Pain Med"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ejphar.2005.06.002","article-title":"The effects of curcumin on depressive-like behaviors in mice.","volume":"518","author":"Xu","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1213\/00000539-199204000-00010","article-title":"Subjective, behavioral, and physiologic responses to intravenous dezocine in healthy volunteers.","volume":"74","author":"Zacny","year":"1992","journal-title":"Anesth Analg"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"e0233412","DOI":"10.1371\/journal.pone.0233412","article-title":"Postoperative analgesia using dezocine alleviates depressive symptoms after colorectal cancer surgery: a randomized, controlled, double-blind trial.","volume":"15","author":"Zhao","year":"2020","journal-title":"PLoS One"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000641","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:04:00Z","timestamp":1749938640000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000641"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,3]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000641","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,3]]}}}